Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy.

ABSTRACT: Immunosuppressive cells in the tumor microenvironment allow cancer cells to escape immune recognition and support cancer progression and dissemination. To improve therapeutic efficacy, we designed a liposomal oxaliplatin formulation (PCL8-U75) that elicits cytotoxic effects toward both cancer and immunosuppressive cells via protease-mediated, intratumoral liposome activation. The PCL8-U75 liposomes displayed superior therapeutic efficacy across all syngeneic cancer models in comparison to free-drug and liposomal controls. The PCL8-U75 depleted myeloid-derived suppressor cells and tumor-associated macrophages in the tumor microenvironment. The combination of improved cancer cell cytotoxicity and depletion of immunosuppressive populations of immune cells is attractive for combination with im

SUBMITTER: Ringgaard L 

PROVIDER: S-EPMC7473747 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature